Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the combination of alemtuzumab and
rituximab is safe and effective in treating patients with relapsed Chronic Lymphocytic
Leukemia (CLL) and to determine whether alemtuzumab can be given as a single weekly
subcutaneous dose, together with rituximab.